S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
pixel
Log in
NASDAQ:EVLO

Evelo Biosciences Stock Forecast, Price & News

$9.86
-0.13 (-1.30 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.74
Now: $9.86
$10.66
50-Day Range
$9.71
MA: $15.05
$18.60
52-Week Range
$3.01
Now: $9.86
$19.93
Volume161,698 shs
Average Volume271,086 shs
Market Capitalization$468.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis; EDP1867 for asthma; EDP2939 for inflammatory disease; and EDP1632 for neuro-inflammatory diseases. In addition, it is developing EDP1503, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Evelo Biosciences logo

Headlines

Stock Alert: Evelo Biosciences Jumps 43%
December 14, 2020 |  nasdaq.com
Evelo Biosciences: Clinical Data Coming Soon
November 10, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVLO
CUSIPN/A
Phone617-577-0300
Employees98
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.88 per share

Profitability

Net Income$-85,470,000.00

Miscellaneous

Market Cap$468.05 million
Next Earnings Date3/9/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

98th out of 1,971 stocks

Pharmaceutical Preparations Industry

39th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
$9.86
-0.13 (-1.30 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVLO News and Ratings via Email

Sign-up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions

Is Evelo Biosciences a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Evelo Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares.
View analyst ratings for Evelo Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Evelo Biosciences?

Wall Street analysts have given Evelo Biosciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evelo Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Evelo Biosciences' next earnings date?

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Evelo Biosciences
.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) posted its quarterly earnings results on Thursday, October, 29th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.50) by $0.05.
View Evelo Biosciences' earnings history
.

How has Evelo Biosciences' stock price been impacted by COVID-19?

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EVLO stock has increased by 125.6% and is now trading at $9.86.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EVLO?

5 brokers have issued 12-month target prices for Evelo Biosciences' stock. Their forecasts range from $6.00 to $36.00. On average, they expect Evelo Biosciences' share price to reach $18.25 in the next twelve months. This suggests a possible upside of 85.1% from the stock's current price.
View analysts' price targets for Evelo Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Evelo Biosciences' key executives?

Evelo Biosciences' management team includes the following people:
  • Dr. Balkrishan Gill, Pres, CEO, Treasurer, Principal Financial Officer & Director (Age 56)
  • Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 63)
  • Ms. Xiaoli Liu, Controller & Principal Accounting Officer (Age 46)
  • Dr. Chun Zhang, Head of Technical Operations
  • Mr. Stefan Riley, Head of Investor Relations
  • Mr. Daniel S. Char, Gen. Counsel & Sec. (Age 60)
  • Ms. Jessica Cotrone, VP & Head of Communications
  • Ms. Julie Carretero, Chief People Officer
  • Dr. Andrea Itano Ph.D., Head of Research
  • Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 54)

Who are some of Evelo Biosciences' key competitors?

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Who are Evelo Biosciences' major shareholders?

Evelo Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Credit Suisse AG (5.70%), BlackRock Inc. (2.74%), Artal Group S.A. (1.47%), Northern Trust Corp (0.48%), Charles Schwab Investment Management Inc. (0.28%) and Bank of New York Mellon Corp (0.12%). Company insiders that own Evelo Biosciences stock include David R Epstein, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends for Evelo Biosciences
.

Which institutional investors are selling Evelo Biosciences stock?

EVLO stock was sold by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC, Charles Schwab Investment Management Inc., and Barclays PLC.
View insider buying and selling activity for Evelo Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Evelo Biosciences stock?

EVLO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Artal Group S.A., Credit Suisse AG, JPMorgan Chase & Co., Bank of New York Mellon Corp, Jane Street Group LLC, The Manufacturers Life Insurance Company , and Larson Financial Group LLC. Company insiders that have bought Evelo Biosciences stock in the last two years include David R Epstein, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Evelo Biosciences
or or view top insider-buying stocks.

How do I buy shares of Evelo Biosciences?

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $9.86.

How much money does Evelo Biosciences make?

Evelo Biosciences has a market capitalization of $468.05 million. The company earns $-85,470,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis.

How many employees does Evelo Biosciences have?

Evelo Biosciences employs 98 workers across the globe.

What is Evelo Biosciences' official website?

The official website for Evelo Biosciences is www.evelobio.com.

Where are Evelo Biosciences' headquarters?

Evelo Biosciences is headquartered at 620 Memorial Drive Suite 500 West, Cambridge MA, 02139.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]


This page was last updated on 3/9/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.